Sensory Medical raises $1.4m for Relaxis restless legs treatment
Sensory Medical shook a leg on a 2nd tranche of funding since receiving FDA clearance last spring for its device to relieve symptoms of restless legs syndrome, reporting $1.4 million in fresh funding on the heels of a $1 million tranche in June.
Allergan CEO Pyott steps down from Edwards Lifesciences board | Personnel Moves
Restless Leg Syndrome: FDA approves 1st non-drug treatment
FDA regulators this week cleared the 1st non-drug therapy for restless leg syndrome, Sensory Medical’s Relaxis system.
MassDevice Network
@MassDevice
LinkedIn
YouTube